Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 11/20 | 0.55 |
| ▸ | MMP8 | P22894 | 10/20 | 0.55 |
| ▸ | CTSD | P07339 | 2/20 | 0.51 |
| ▸ | MMP1 | P03956 | 2/20 | 0.51 |
| ▸ | FCER2 | P06734 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 8/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | MMP7 | P09237 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5558596 | 0.85 | CTSD (0.49) | MMP9MMP8CTSDMGLLKMT2A | |
| SCHEMBL5557538 | 0.80 | MMP9 (0.80) | MMP9MMP8MMP1FCER2MMP2 | |
| SCHEMBL5558630 | 0.80 | MMP9 (0.80) | MMP9MMP8MMP1FCER2MMP2 | |
| SCHEMBL12573089 | 0.77 | MGLL (0.52) | CTSDMGLLKMT2AALDH1A1POLB | |
| SCHEMBL5556727 | 0.77 | MMP9 (0.59) | MMP9MMP8MMP1FCER2MMP2 | |
| SCHEMBL5558476 | 0.75 | MMP9 (0.60) | MMP9MMP8MMP1FCER2MMP2 | |
| SCHEMBL17335700 | 0.75 | MGLL (0.57) | CTSDMGLLKMT2AALDH1A1POLB | |
| SCHEMBL5552823 | 0.72 | MMP9 (0.62) | MMP9MMP8MMP1FCER2MMP2 | |
| SCHEMBL7979588 | 0.72 | MGLL (0.60) | CTSDMGLLKMT2AALDH1A1POLB | |
| SCHEMBL5556787 | 0.70 | ERAP2 (0.69) | MMP9MMP8MMP1FCER2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2005027856-A2 | INHIBITORS OF ANTHRAX LETHAL FACTOR | CENGENT THERAPEUTICS (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | MMP9 182/4885MMP8 24/4885CTSD 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.